Brazil’s federal health ministry began dispensing nine new cancer drugs through the public Sistema Único de Saúde (SUS) network this week, for more than 116,000 patients, and expects all 23 drugs in its oncology package to be available by year-end at an estimated R$4 billion a year.
MARKET ACCESS · ONCOLOGY ACCESS · OCTOBER 22, 2026 · BRAZIL
A long-pending incorporation decision is starting to reach patients. The Ministério da Saúde, Brazil’s federal health ministry, began dispensing nine new high-technology oncology medicines through the Sistema Único de Saúde (SUS), the country’s universal public health system, from the week of October 20, initially at 20 treatment centres in 17 states, with more than 116,000 patients expected to benefit, according to a ministry release. The ministry expects 23 new cancer drugs in the public network by the end of the year.
The full 23-medicine package — which the ministry described in a July statement to Folha as ‘the largest delivery ever made by the SUS to expand population access to cancer treatments’ — was costed at R$2.2 billion and more than 112,000 patients when announced; the ministry’s October release puts the plan’s impact at R$4 billion a year. The ministry told Folha in July that some pending incorporations had been outstanding for up to 12 years; its October release says many of the drugs had been awaited for more than ten years.
The ALK-positive gap that drove the urgency
Among the drugs in the 23-drug package, though not in the first nine now being dispensed, is brigatinib, a targeted therapy for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in advanced or metastatic stages. The ministry confirmed to Folha that brigatinib had been unavailable in the SUS prior to this rollout — an admission that frames its eventual arrival as a resolution of a documented access failure rather than a routine formulary update.
The clinical stakes of that gap are quantified in two Brazilian studies published in June in JCO Global Oncology, the journal of the American Society of Clinical Oncology (ASCO). One of the studies, of 101 patients, found that patients with ALK-positive NSCLC treated through the SUS had overall survival of about 1.8 years, compared with 5.8 years for patients treated in the private sector. ALK alterations are present in 3.2% of NSCLC cases, according to Folha, and the affected population skews toward non-smokers in their fifties.
The survival differential is not reducible to drug access alone. Reports from CONITEC (Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde), Brazil’s health-technology assessment body, document that between 85% and 93% of SUS lung cancer patients are already at advanced stages at the time of diagnosis — a structural diagnostic gap that brigatinib’s availability cannot by itself address. The ministry acknowledged to Folha that regional disparities in immunohistochemistry testing for ALK alterations persist, attributing them to infrastructure variation across oncology-certified facilities and to negotiation dynamics between states and municipalities.
Fiscal architecture and the 23-drug commitment
The R$2.2 billion figure reported by Folha in July, and the R$4 billion a year the ministry now cites, represent a significant public commitment; the ministry frames the package as a 35% increase in the supply of oncology drugs available through the public network.
A separate procurement lever, aimed at rare diseases rather than oncology, shows how the ministry expects public-sector prices to fall over time. Fernanda De Negri, then Secretary of Science, Technology and Innovation and the Health-Economic-Industrial Complex (SECTICS), stated to Valor Econômico that Productive Development Partnerships (PDPs) — ten-year technology-transfer agreements with public manufacturers including the Fundação Oswaldo Cruz (Fiocruz), Brazil’s public biomedical research institution, and the Instituto Butantan — are expected to reduce acquisition prices by 5% to 10% over the partnership period, with further declines projected thereafter. The ministry estimates that seven rare-disease medicines selected under PDPs move R$2 billion annually through the SUS, per Valor’s June 2025 reporting.
The counterweight to the October timeline is operational. A ministry announcement is not a stocked dispensing unit. Part of the package depends on state-level purchasing — the ministry buys 10 of the 23 drugs directly, nine through a joint price registry with states and funds four through transfers — and the gap between a federal incorporation decision and physical availability at a dispensing pharmacy has historically stretched well beyond the announced start date. The brigatinib case itself illustrates the risk: the drug had been incorporated by CONITEC before this announcement, yet remained unavailable to SUS patients until the ministry’s current commitment. Manufacturers entering the public channel face the same sequencing risk: a listed price and a signed agreement do not guarantee predictable order flow, as Hypera Pharma’s institutional-channel results in the second quarter of 2025 illustrated — the company reported to Valor that the public sector conducted procurement tenders but that the number of concretized orders decelerated in that period.
What to Watch
- Whether the first nine drugs extend beyond the initial 20 centres to the rest of the country by year-end, as the ministry expects, or whether state-level procurement lags extend the effective access date beyond the federal announcement
- Whether the remaining 14 medicines in the 23-drug package reach patients by the ministry’s year-end target
- Regional ALK-testing infrastructure: the ministry’s acknowledgment of diagnostic disparities means that even with brigatinib available, the share of eligible SUS patients who receive the molecular test required to qualify for the therapy remains a binding constraint on real-world uptake
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
You're in. The next Brief lands in your inbox.
The deeper asymmetry in this rollout is diagnostic, not pharmacological. Closing the 1.8-year versus 5.8-year survival gap requires that patients reach an ALK test before they reach an advanced stage — and that sequencing problem sits upstream of every drug the ministry can now dispense.
SUS Oncology Rollout · ALK-Positive Lung Cancer
| SUS Patients | Private-Sector Patients | |
|---|---|---|
| Overall survival, ALK-positive non-small-cell lung cancer | 1.8 years | 5.8 years |
| Advanced-stage lung cancer at diagnosis | 85–93% |
Sources: JCO Global Oncology (two Brazilian studies, June 2026); CONITEC reports (cited in Folha de S.Paulo, July 2026)
Why this is relevant
Patients
Cancer patients began receiving the first nine of 23 new high-cost oncology medicines through the SUS in October 2026; brigatinib, for ALK-positive non-small cell lung cancer (NSCLC), is in the package but not yet in the first nine. The survival gap documented in JCO Global Oncology — 1.8 years in the public sector versus 5.8 years in the private sector for ALK-positive NSCLC patients — suggests that drug availability alone will not close the outcome differential while diagnostic infrastructure gaps persist.
Industry
Manufacturers whose products enter the SUS public channel gain volume at scale but accept negotiated acquisition prices and face sequencing risk: a federal incorporation announcement does not guarantee timely state-level procurement, as Hypera Pharma’s institutional-channel deceleration in mid-2025 illustrated. The 23-drug rollout, which the ministry now puts at R$4 billion a year, represents a defined but operationally complex revenue opportunity.
Payers
The ministry’s estimated R$4 billion a year for 23 medicines establishes a new baseline for SUS oncology spending. The Agência Nacional de Saúde Suplementar (ANS), Brazil’s private-health regulator, may face pressure to align supplementary-sector coverage obligations as SUS incorporations expand, though no formal ANS action has been announced in connection with this rollout.
Regulators
CONITEC (Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde), Brazil’s health-technology assessment body, has completed incorporation reviews for the drugs in this tranche; the ministry’s acknowledgment that some pending incorporations had been outstanding for up to 12 years points to a backlog-clearance dynamic. Regional disparities in ALK molecular testing infrastructure remain an unresolved logistical constraint on real-world uptake.
Sources: Ministério da Saúde: Ministério da Saúde inicia oferta no SUS de nove medicamentos oncológicos · Folha de S.Paulo: Pacientes com câncer de pulmão vivem menos no SUS, mostra estudo · Valor Econômico: Parceria entre indústria e governo amplia atendimento a doenças raras · Valor Econômico: Vendas no mercado institucional registram queda no 2º tri, diz Hypera
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.
Your subscription could not be validated.
You have successfully subscribed.
